Lp(a) Test: Which Labs to Order Alongside It and What Your Results Mean

What Lp(a) Is and Why Women Need to Know

Lp(a), pronounced "L-P-little-a," is a low-density lipoprotein particle with an extra protein called apolipoprotein(a) attached to it. That attachment makes it stickier, more pro-inflammatory, and harder for your body to clear. Elevated Lp(a) is one of the most common inherited risk factors for cardiovascular disease, affecting roughly 1 in 5 people globally.

Most lipid panels your doctor orders do not include Lp(a). Standard LDL calculations actually partially incorporate Lp(a) mass, which means a woman with very high Lp(a) can appear to have a modest LDL when her true atherogenic particle burden is much higher. That gap is clinically meaningful.

Why This Is a Women's Health Issue

Heart disease is the leading cause of death in American women, responsible for 1 in every 5 female deaths. Yet women are systematically undertreated for cardiovascular risk, in part because traditional risk calculators underperform in women and miss Lp(a) entirely.

Women also experience a hormonal inflection point that men do not. Estrogen suppresses hepatic Lp(a) production. When estrogen falls at menopause, Lp(a) can climb. A 2022 analysis published in the journal Menopause found that Lp(a) concentrations were significantly higher in postmenopausal women compared with premenopausal controls, even after adjusting for age and BMI. This is not a trivial finding for a protein that is otherwise almost entirely genetically determined.

How Lp(a) Differs from LDL

| Feature | LDL | Lp(a) | |---|---|---| | Primary determinant | Diet, lifestyle, genetics | Genetics (>90%) | | Modifiable by diet | Yes, meaningfully | Minimally | | Included in standard lipid panel | Yes | No, must order separately | | Raises clot risk | Indirect | Direct (inhibits fibrinolysis) | | Standard statin response | 30-50% reduction | Little to no reduction |

What Is a Normal Lp(a) Level?

The answer depends on the units your lab uses. Two common unit systems exist and they are not interchangeable.

In nmol/L (the unit increasingly preferred because it measures particle number directly): <75 nmol/L is low risk, 75-124 nmol/L is borderline, and ≥125 nmol/L is high risk, per the 2019 European Society of Cardiology and European Atherosclerosis Society dyslipidaemia guidelines.

In mg/dL (older mass-based unit, still common in U.S. Labs): <30 mg/dL is generally cited as acceptable, with ≥50 mg/dL considered elevated.

A 2022 American Heart Association scientific statement noted that approximately 20-25% of the U.S. Population has Lp(a) levels above the high-risk threshold. If you received your result in mg/dL and want the nmol/L equivalent, do not multiply by a fixed conversion factor. The relationship is nonlinear because apolipoprotein(a) isoform size varies between individuals.

The Range Is Genetic, Not Lifestyle-Driven

This is the piece most women find surprising. You cannot meaningfully lower your Lp(a) by eating less saturated fat, walking more, or losing weight. The level your liver produces is set, almost entirely, by variants in the LPA gene on chromosome 6. Knowing this matters because it shifts the clinical conversation from blame to surveillance and, increasingly, to targeted therapy.

Which Tests to Order Alongside Lp(a)

No single lab number tells a complete cardiovascular risk story. Lp(a) should sit inside a panel that captures atherogenic particle burden, inflammation, metabolic health, and blood pressure. The following framework is what WomanRx clinicians use when reviewing a woman's first Lp(a) result.

Tier 1: Always Order Together

Full fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides) Your LDL-C number underestimates risk when Lp(a) is high, because Lp(a) mass is partially included in the LDL-C calculation by the Friedewald equation. A woman with Lp(a) of 150 nmol/L and an LDL-C of 110 mg/dL has a higher true atherogenic burden than the LDL number suggests. Per the 2018 AHA/ACC Cholesterol Guideline, Lp(a) ≥50 mg/dL is a "risk-enhancing factor" that warrants consideration of intensified statin therapy even when calculated 10-year risk is in the borderline zone.

Apolipoprotein B (apoB) ApoB measures the total number of atherogenic particles directly. One apoB molecule sits on every LDL, IDL, VLDL, and Lp(a) particle. An apoB result captures all of them. For a woman whose Lp(a) is elevated, apoB ≥130 mg/dL confirms that her total atherogenic particle burden is high, which sharpens the case for treatment. AACE 2017 lipid guidelines list apoB as a preferred secondary target in high-risk patients.

High-sensitivity C-reactive protein (hs-CRP) Lp(a) is itself pro-inflammatory, but hs-CRP captures systemic vascular inflammation from all sources. A woman with high Lp(a) and hs-CRP ≥2 mg/L carries compounded risk. The JUPITER trial showed that statin therapy in patients with elevated hs-CRP but low LDL reduced cardiovascular events by 44%, data that are particularly relevant for women with elevated Lp(a) who would otherwise fall below the LDL-C treatment threshold.

Blood pressure (two separate readings) Hypertension and elevated Lp(a) act synergistically on arterial wall stress. According to AHA statistics, approximately 57% of women over 55 have hypertension. Documenting current blood pressure at the time of Lp(a) testing anchors the risk calculation.

Tier 2: Order Based on Life Stage and Clinical Context

Fasting glucose or HbA1c Insulin resistance amplifies cardiovascular risk even when Lp(a) is modestly elevated. Women with PCOS carry both higher rates of insulin resistance and, in some studies, higher Lp(a) concentrations. A 2020 meta-analysis in Fertility and Sterility found Lp(a) significantly elevated in women with PCOS compared to controls. HbA1c or fasting glucose should be part of every PCOS-related workup that includes Lp(a).

Thyroid-stimulating hormone (TSH) Hypothyroidism raises LDL and may worsen the overall atherogenic profile. Women are five to eight times more likely than men to develop thyroid disease, and postpartum thyroiditis affects roughly 5-10% of postpartum women. Excluding thyroid dysfunction before attributing a lipid pattern entirely to Lp(a) genetics is basic due diligence.

Lipoprotein-associated phospholipase A2 (Lp-PLA2) (if available) Lp-PLA2 travels predominantly on LDL and Lp(a) particles. Elevated Lp-PLA2 alongside high Lp(a) further characterises vascular wall inflammation and may refine risk in women who are borderline for statin initiation. Evidence for clinical utility remains less definitive than for apoB or hs-CRP, so treat this as optional rather than standard.

Coronary artery calcium (CAC) score CAC is not a blood test, but it belongs in the same conversation. A CAC score of zero in a woman with elevated Lp(a) and no other risk factors allows a reasonable discussion about deferring statin initiation. A CAC score above 100 or above the 75th percentile for age, sex, and ethnicity strengthens the case for immediate lipid-lowering therapy. The 2018 AHA/ACC guideline recommends CAC as the preferred tool for reclassifying risk when the treatment decision is uncertain.

Tier 3: Order at Perimenopause and Post-Menopause

Repeat Lp(a) if starting or stopping hormone therapy Oral estrogen lowers Lp(a) by 20-30%, an effect not seen with transdermal estrogen. If you start oral combined hormone therapy, your Lp(a) result obtained before therapy may no longer reflect your current cardiovascular risk accurately. Conversely, if you stop oral estrogen, Lp(a) may rebound. A 2003 study in Arteriosclerosis, Thrombosis, and Vascular Biology confirmed this route-dependent effect and its reversal on cessation.

Bone density (DXA scan) Women with very high Lp(a) have a higher prevalence of aortic valve calcification and may have shared vascular-skeletal risk mechanisms. This is a less proven association, but for a postmenopausal woman already undergoing cardiovascular risk stratification, DXA at age 65 (or earlier per USPSTF recommendations if risk factors apply) fits naturally into the same appointment planning.

How Hormones, Menopause, and Reproduction Change Lp(a)

Reproductive Years

Lp(a) levels in premenopausal women are generally lower than in age-matched men, reflecting estrogen's suppressive effect on hepatic LPA gene expression. This relative protection disappears at menopause. During the reproductive years, a woman whose Lp(a) is already elevated at, say, 130 nmol/L on a baseline test at age 30 should not assume her risk is stable. The absence of new life-stage data is not reassurance; it is a gap.

Perimenopause

Perimenopause is the transition period, typically spanning 4-10 years before the final menstrual period, during which estrogen levels fluctuate widely before falling. Lp(a) may begin to rise during this window even before menstrual cycles become irregular. The Menopause Society's 2022 position statement on cardiovascular disease identifies Lp(a) among the emerging biomarkers that deserve attention in cardiovascular risk assessment during this transition.

Women in perimenopause who have a strong family history of early heart disease (first-degree relative with MI before 55 in a man, before 65 in a woman) should have Lp(a) tested regardless of their standard lipid numbers.

Post-Menopause

After the final menstrual period, the Lp(a)-raising effect of estrogen loss can persist. The clinical implication: a woman who had Lp(a) tested at age 40 and received a borderline result should consider retesting 1-2 years after her final menstrual period. Her number may have moved from a zone of watchful waiting into a zone requiring active management.

PCOS

Women with PCOS frequently present with atherogenic dyslipidaemia, high triglycerides, low HDL, and elevated small dense LDL. Adding Lp(a) to the workup in PCOS is supported by the 2020 Fertility and Sterility meta-analysis cited above, which found mean Lp(a) was 8.4 mg/dL higher in PCOS patients than controls. Given that PCOS already carries a two-to-four-fold higher cardiovascular risk, this additional Lp(a) burden is clinically meaningful.

Pregnancy and Lp(a): What You Need to Know

Lp(a) is not a standard prenatal lab. However, certain pregnancy-related considerations apply directly.

Physiologic rise in pregnancy. Lp(a) rises substantially during normal pregnancy, particularly in the third trimester, as part of a broader shift toward a pro-coagulant, pro-inflammatory state that serves placental function. A result obtained during pregnancy will be artifactually elevated compared to your non-pregnant baseline. Do not use pregnancy Lp(a) values to diagnose elevated Lp(a) or make long-term treatment decisions.

Preeclampsia and placental thrombosis. Elevated Lp(a) has been associated with increased risk of preeclampsia and adverse placental outcomes, likely because Lp(a) inhibits plasminogen activation and promotes clot formation in placental vessels. Women with a personal or family history of early-onset preeclampsia should consider Lp(a) testing postpartum, once levels have returned to baseline (typically 6-12 weeks after delivery).

No drug treatment during pregnancy. There are no approved Lp(a)-lowering medications safe for use in pregnancy. PCSK9 inhibitors (evolocumab, alirocumab) carry limited human pregnancy data and are generally avoided. The investigational RNA therapies targeting Lp(a) (pelacarsen, olpasiran, lepodisiran) are in phase 3 trials and have not been studied in pregnant women. Statins are contraindicated in pregnancy. If you have high Lp(a) and are planning a pregnancy, discuss timing with your clinician before any pharmacologic intervention.

Postpartum retesting. Test Lp(a) no sooner than 12 weeks postpartum to get a representative baseline. Breastfeeding does not meaningfully alter Lp(a) levels, but the return of normal ovulatory cycles will gradually restore the modest estrogen-mediated suppression seen in premenopausal women.

What a High Lp(a) Means and What to Do About It

A high Lp(a) (≥125 nmol/L or ≥50 mg/dL) means you inherited a genetic variant that causes your liver to overproduce this atherogenic lipoprotein. It does not mean a heart attack is inevitable. It means your cardiovascular risk is higher than your LDL-C alone suggests, and your other modifiable risk factors deserve more aggressive control.

Steps After a High Result

1. Lower every modifiable risk factor aggressively. Blood pressure below 120/80 mmHg, LDL-C below 70 mg/dL (or 55 mg/dL if you have established heart disease), no smoking, HbA1c below 5.7%, and sustained physical activity. These targets are set lower than for average-risk individuals.

2. Discuss statin initiation with your clinician. Even though statins do not lower Lp(a) directly, they substantially reduce overall atherogenic risk when LDL-C is also elevated. The 2018 AHA/ACC guideline supports using Lp(a) ≥50 mg/dL as a risk-enhancing factor when deciding whether to start or intensify statin therapy in intermediate-risk patients.

3. Ask about PCSK9 inhibitors. Evolocumab and alirocumab each lower Lp(a) by roughly 20-30% in addition to their primary LDL-C lowering effect. For a woman with Lp(a) of 200 nmol/L, this reduction still leaves her above the high-risk threshold, but it may reduce absolute particle burden enough to matter clinically.

4. Watch for clinical trials. Pelacarsen, an antisense oligonucleotide targeting LPA mRNA, reduced Lp(a) by a median of 72% in the phase 2 Lp(a)HORIZON trial. The phase 3 trial is ongoing. Olpasiran, a small interfering RNA, reduced Lp(a) by more than 90% in the OCEAN(a)-DOSE trial. These are not yet approved, but they represent the most promising pharmacologic development in this space in decades.

5. Screen first-degree relatives. Because Lp(a) is genetically determined, a daughter, sister, or mother of a woman with high Lp(a) has a substantially higher-than-population chance of sharing the same risk. European Atherosclerosis Society guidance recommends cascade testing.

Lp(a) and Aortic Valve Disease

High Lp(a) is independently associated with calcific aortic valve stenosis, a condition that disproportionately progresses silently until it becomes severe. Women with Lp(a) above 150 nmol/L and any cardiac murmur should have a focused echocardiogram to assess valve calcification, even without symptoms.

What a Low Lp(a) Means

A low Lp(a) (<75 nmol/L, or <30 mg/dL) is generally reassuring. It means this particular genetic risk factor is not contributing meaningfully to your cardiovascular risk calculation.

Low Lp(a) does not eliminate the need for other lipid testing. A woman with Lp(a) of 20 nmol/L can still have an LDL-C of 180 mg/dL, triglycerides of 400 mg/dL, or severe hypertension. The rest of the risk picture still applies.

There is no clinical benefit to having Lp(a) below a certain floor. Very low Lp(a) has been associated in some epidemiologic datasets with a slightly higher rate of type 2 diabetes, but this association is modest and does not warrant any clinical action.

Who Should Get Lp(a) Tested

Not every woman needs this test today. The following groups should prioritise it.

Strong indication:

• Personal or family history of premature cardiovascular disease (MI or stroke before 55 in a male relative, before 65 in a female relative)
• LDL-C that remains elevated despite maximal statin therapy
• Recurrent cardiovascular events despite apparently well-controlled lipids
• Calcific aortic valve stenosis at any age
• Personal history of preeclampsia or placental abruption
• PCOS with additional cardiovascular risk factors

Reasonable consideration:

• Perimenopause or post-menopause with intermediate cardiovascular risk by 10-year calculator
• Starting hormone therapy: document baseline before any Lp(a)-altering intervention

Testing once is usually sufficient. Lp(a) changes less than 10% over a person's lifetime outside of the hormonal exceptions noted above. The European Atherosclerosis Society and the National Lipid Association both recommend a single measurement in adults, repeated only when clinical circumstances change (hormone therapy initiation, menopause transition, or before a major treatment decision).

The Evidence Gap for Women

Women have been underrepresented in Lp(a) cardiovascular outcomes trials. The FOURIER trial of evolocumab, for example, enrolled 27% women. The ODYSSEY OUTCOMES trial enrolled 25% women. Phase 3 Lp(a)-specific trials are aiming for better representation but have not yet reported sex-stratified outcomes.

What this means practically: dose thresholds and risk-reclassification cutoffs derived from these trials may not translate perfectly to women. Clinicians should treat Lp(a) thresholds as approximations in individual women rather than bright-line decision rules. The honest answer is that we have good mechanistic data and observational evidence in women, but sex-specific randomised trial data on Lp(a)-targeted therapy does not yet exist.

"Every woman who has ever had a cardiovascular event while her LDL appeared controlled deserves an Lp(a) measurement. We have been leaving this number off the requisition form for decades and calling it a complete workup.", Elena Vasquez, MD, WomanRx Medical Reviewer and Preventive Cardiologist

Practical Next Steps After Your Lp(a) Result

Once you have your number, bring it to your clinician alongside your full lipid panel, apoB, and hs-CRP results. Ask specifically:

• Is my 10-year cardiovascular risk calculation updated to include Lp(a) as a risk-enhancing factor?
• Should my LDL-C target be revised downward given my Lp(a) level?
• Do I need a coronary artery calcium scan to decide about statin therapy?
• Should any first-degree female relatives be tested?

If you are in perimenopause, post-menopause, or have PCOS, add: does my hormonal status affect how we interpret or retest this number?

Your clinician should be able to answer each of these questions directly. If the conversation stays at "your cholesterol looks fine," that answer is not sufficient when Lp(a) is elevated.